Results 11 to 20 of about 503,933 (311)

Targeting the epidermal growth factor receptor [PDF]

British Journal of Cancer, 2004
The epidermal growth factor receptor (EGFR) is a member of the erbB family of tyrosine kinase receptors (RTK). The EGFR is involved in cell proliferation, metastasis and angiogenesis, and is expressed in a large proportion of epithelial tumours. The two main classes of EGFR inhibitors in clinical trials are the RTK inhibitors and the monoclonal ...
El-Rayes, B F, LoRusso, P M
openaire   +2 more sources

Epidermal growth factor receptor signaling [PDF]

Current Biology, 2001
Inhibitory signaling is an important way of fine tuning EGFR activity to enable a cell to discriminate between short and prolonged exposure to signaling molecules. Over the last few years a number of different mechanisms have been shown to abrogate receptor activity (Fig. 3Fig. 3). First, inhibitory signaling molecules are expressed in response to EGFR
Bogdan, Sven, Klämbt, Christian
openaire   +2 more sources

The epidermal growth factor receptor conundrum [PDF]

Cancer, 2010
Soluble epidermal growth factor receptor (sEGFR), a cell surface and serum protein derived from an alternately spliced human EGFR transcript, is recognized by 2 therapeutic antibodies approved by the US Food and Drug Administration: cetuximab and panitumumab.
Jason A, Wilken, Andre T, Baron, Nita J, Maihle   +2 more
openaire   +2 more sources

Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma [PDF]

, 2018
Rationale:Small bowel adenocarcinoma (SBA) is an uncommon gastrointestinal cancer, thus limited data about treatment for advanced disease are available.
Anselmi, Elisabetta, Falcone, Rosa, Filetti, Marco, Marchetti, Paolo, Roberto, Michela   +4 more
core   +1 more source

Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy

Genome Medicine, 2017
Targeted therapies such as kinase inhibitors and monoclonal antibodies have dramatically altered cancer care in recent decades. Although these targeted therapies have improved patient outcomes in several cancer types, resistance ultimately develops to ...
Leanne G. Ahronian, Ryan B. Corcoran
doaj   +1 more source

Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium [PDF]

, 2014
Breast cancer risk factors and clinical outcomes vary by tumour marker expression. However, individual studies often lack the power required to assess these relationships, and large-scale analyses are limited by the need for high throughput, standardized
Ali, H Raza, Benitez, Javier, Blomqvist, Carl, Blows, Fiona M, Bolla, Manjeet K, Brinton, Louise, Brock, Ian W, Broeks, Annegien, Brook, Mark N, Caldas, Carlos, Couch, Fergus J, Coulson, Penny, Cox, Angela, Cross, Simon S, Daley, Frances, Dawson, Sarah-Jane, Devillee, Peter, Easton, Douglas F, Fagerholm, Rainer, Figueroa, Jonine, García-Closas, Montserrat, Gazinska, Patrycja, Heikkilä, Päivi, Hollestelle, Antoinette, Howat, William J, Johnson, Nicola, Jones, Louise, Kataja, Vesa, Kosma, Veli-Matti, Lissowska, Jolanta, Mannermaa, Arto, McDuffus, Leigh-Anne, Menéndez, Primitiva, Mesker, Wilma E, Miller, Jodi, Morris, Lorna, Nevanlinna, Heli, Olson, Janet E, Perez, Jose Ignacio Arias, Pharoah, Paul D, Pinder, Sarah, Provenzano, Elena, Reed, Malcolm W, Sanders, Joyce, Sawyer, Elinor J, Schmidt, Marjanka K, Seyaneve, Caroline M, Sherman, Mark E, Sironen, Reijo, van Deurzen, Carolien H M, Visscher, Daniel, Wesseling, Jelle   +51 more
core   +6 more sources

Epidermal growth factor receptor in glioblastoma

Oncology Letters, 2017
Mutations in the epidermal growth factor receptor (EGFR) are commonly occurring in glioblastoma. Enhanced activation of EGFR can occur through a variety of different mechanisms, both ligand-dependent and ligand-independent. Numerous evidence has suggested that EGFR is overexpressed in most of primary glioblastomas and some of the secondary ...
Xu, Hongsheng, Zong, Hailiang, Ma, Chong, Ming, Xing, Shang, Ming, Li, Kai, He, Xiaoguang, Du, Hai, Cao, Lei   +8 more
openaire   +3 more sources

Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

Tumor Biology, 2017
The finding of epidermal growth factor receptor tyrosine kinase inhibitors, which reflects a classical process of translational research, is a critical milestone for non-small-cell lung cancer treatment.
Shaohua Cui, Liyan Jiang
doaj   +1 more source

Prevalence of Epidermal Growth Factor Receptor Mutations in Patients with Non-Small Cell Lung Cancer in Turkish Population

Balkan Medical Journal, 2017
Aims: Epidermal growth factor receptor mutation analysis in non-small cell lung cancer is important for selecting patients who will receive treatment with tyrosine kinase inhibitors.
Gaye Güler Tezel, Ebru Şener, Çisel Aydın, Sevgen Önder   +3 more
doaj   +1 more source

Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis

Thoracic Cancer, 2021
Background Differences in the resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor mutations are unknown.
Nobuaki Kobayashi, Seigo Katakura, Chisato Kamimaki, Kohei Somekawa, Nobuhiko Fukuda, Katsushi Tanaka, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Hongmei Piao, Takeshi Kaneko   +10 more
doaj   +1 more source